1. Sharma SK, Dhooria S, Prasad KT, George N, Ranjan S, Gupta D, et al. Outcomes of antiretroviral therapy in a northern Indian urban clinic. Bull World Health Organ. 2010;88(3):222-6. [DOI via Crossref] [Pubmed] [PMC Free Fulltext] |
|
2. Reddy A, Lihite RJ, Lahkar M, Choudhury U, Baruah SK. A study on adverse drug reactions in HIV infected patients at a ART center of tertiary care hospital in Guwahati, India. Asian J Pharm Clin Res 2013;6(2):102-4. |
|
3. Kumarasamy N, Venkatesh KK, Mayer KH, Freedberg K. Financial burden of health services for people with HIV/AIDS in India. Indian J Med Res. 2007;126(6):509-17. |
|
4. The Uppsala Monitoring Center. The Use of the WHO-UMC System for Standardised Case Causality Assessment. Available from: http://www.who-umc.org/Graphics/24734.pdf. [Last cited on 2016 May 18]. |
|
5. Mrugank BP, Hareesh RP. Prospective observational, nonrandomized, parallel sequence study for assessment of adverse drug reactions due to chemotherapeutic treatment in different types of cancer patients. IJPSR 2013;4(1):386-91. |
|
6. Council for International Organization for Medical Science (CIOMS). WGI, Guidelines for Preparing Core Clinical Safety Information on Drugs. Geneva: Council for International Organization for Medical Sciences; 1994. Available from: http://www.cioms.ch/publications/reporting_adverse_drug. pdf. [Last cited on 2016 May 18]. |
|
7. Masenyetse LJ, Manda SO, Mwambi HG. An assessment of adverse drug reactions among HIV positive patients receiving antiretroviral treatment in South Africa. AIDS Res Ther. 2015;12:6. [DOI via Crossref] [Pubmed] [PMC Free Fulltext] |
|
8. National Aids Control Organisation. ART Guidelines for HIVInfected Adults and Adolescents Including Post-Exposure Prophylaxis. New Delhi: NACO; 2013. Available from: http:// www.naco.gov.in/upload/Policies%20&%20Guidelines/ Antiretroviral%20Therapy%20Guidelines%20for%20HIVInfected%20Adults%20and%20Adolescents.pdf. [Last citedon 2016 May 18]. |
|
9. Srikanth BA, Babu SC, Yadav HN, Jain SK. Incidence of adverse drug reactions in human immune deficiency viruspositive patients using highly active antiretroviral therapy. J Adv Pharm Technol Res. 2012;3(1):62-7. |
|
10. Agu KA, Oparah AC. Adverse drug reactions to antiretroviral therapy: Results from spontaneous reporting system in Nigeria. Perspect Clin Res. 2013;4(2):117-24. [DOI via Crossref] [Pubmed] [PMC Free Fulltext] |
|
11. Pollard RB, Robinson P, Dransfield K. Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin Ther. 1998;20(6):1071-92. [DOI via Crossref] |
|
12. Wanke CA. Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy. Available from: http://www.uptodate.com/contents/epidemiologyclinical-manifestations-and-diagnosis-of-hiv-associatedlipodystrophy. [Last cited on 2016 May 18] |
|
13. Leitz G, Robinson P. The development of lipodystrophy on a protease inhibitor-sparing highly active antiretroviral therapy regimen. AIDS. 2000;14:468-9. [DOI via Crossref] [Pubmed] |
|
14. Heath KV, Hogg RS, Chan KJ, Harris M, Montessori V, O'Shaughnessy MV, et al. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS. 2001;15(2):231-9. [DOI via Crossref] [Pubmed] |
|
15. Izzedine H, Isnard-Bagnis C, Hulot JS, Vittecoq D, Cheng A, Jais CK, et al. Renal safety of tenofovir in HIV treatmentexperienced patients. AIDS. 2004;18(7):1074-6. [DOI via Crossref] [Pubmed] |
|
16. Hall AM, Hendry BM, Nitsch D, Connolly JO. Tenofovirassociated kidney toxicity in HIV-infected patients: A review of the evidence. Am J Kidney Dis. 2011;57(5):773-80. [DOI via Crossref] [Pubmed] |
|
17. Grayson ML, editor. Anti-viral drugs. Kucher's the Use of Antibiotics. 6th ed. Section IV. Washington, DC: ASM Press; 2010. p. 2595-612. |
|
18. Reust CE. Common adverse effects of antiretroviral therapy for HIV disease. Am Fam Physician. 2011;83(12):1443-51. |
|
19. Lartey M, Asante-Quashie A, Essel A, Kenu E, Ganu V, Neequaye A. Adverse drug reactions to antiretroviral therapy during the early art period at a tertiary hospital in Ghana. Pan Afr Med J. 2014;18:25. [DOI via Crossref] [Pubmed] [PMC Free Fulltext] |
|
20. Hewitt RG. Abacavir hypersensitivity reaction. Clin Infect Dis. 2002;34(8):1137-42. [DOI via Crossref] [Pubmed] |
|
21. El-Eraky H, Thomas SH. Effects of sex on the pharmacokinetic and pharmacodynamic properties of quinidine. Br J Clin Pharmacol. 2003;56:198-204. [DOI via Crossref] [Pubmed] [PMC Free Fulltext] |
|
22. Ofotokun I, Pomeroy C. Sex differences in adverse reactions to antiretroviral drugs. Top HIV Med. 2003;11(2):55-9. |
|
23. Boffito M, Back DJ, Blaschke TF, Rowland M, Bertz RJ, Gerber JG, et al. Protein binding in antiretroviral therapies. AIDS Res Hum Retroviruses. 2003;19(9):825-35. [DOI via Crossref] [Pubmed] |
|
24. Subbaraman R, Chaguturu SK, Mayer KH, Flanigan TP, Kumarasamy N. Adverse effects of highly active antiretroviral therapy in developing countries. Clin Infect Dis. 2007;45(8):1093-101. [DOI via Crossref] [Pubmed] |
|
25. Chaponda M, Pirmohamed M. Hypersensitivity reactions to HIV therapy. Br J Clin Pharmacol. 2011;71(5):659-71. [DOI via Crossref] [Pubmed] [PMC Free Fulltext] |
|
26. Koopmans PP. Desensitisation preferred to rechallenge to manage ADRs in HIV-positive patients. React Wkly. 1999;748:24. |
|